MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for MADRIGAL PHARMACEUTICALS, INC. (MDGL), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are MDGL insiders buying or selling?
In the last 12 months, MADRIGAL PHARMACEUTICALS, INC. insiders reported 0 open-market purchases ($0) and 28 sales ($81.5M) — net selling of $81.5M. Since June 2018, Trabud has recorded 104 Form 4 filings for MDGL: 12 buys ($162.0M) and 92 sells ($769.5M).
Source: SEC EDGAR Form 4
Key Statistics (June 2018 – Sep 11, 2026)
Total Form 4 filings
104
SEC EDGAR
Insider filers
18
Insider buys (12)
$162.0M
Insider sells (92)
$769.5M
Insider sentiment
Net sellingNet insider flow of $607.4M in net selling since June 2018, and $81.5M in net selling over the last 12 months.
Recent MDGL insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | William John Sibold | President and CEO | Sale | 11.6K | $538.65 | $6.2M | SEC ↗ |
| Aug 20, 2026 | Shannon T Kelley | General Counsel | Sale | 664 | $514.97 | $341.9K | SEC ↗ |
| Jul 21, 2026 | William John Sibold | President and CEO | Sale | 2.5K | $547.30 | $1.4M | SEC ↗ |
| Jun 1, 2026 | David Soergel | Chief Medical Officer | Sale | 1.0K | $495.74 | $516.6K | SEC ↗ |
| May 22, 2026 | Richard S Levy | Director | Sale | 5.7K | $515.44 | $2.9M | SEC ↗ |
| May 18, 2026 | David Soergel | Chief Medical Officer | Sale | 844 | $515.90 | $435.4K | SEC ↗ |
| Mar 7, 2026 | Mardi Dier | EVP and CFO | Sale | 2.0K | $430.87 | $854.0K | SEC ↗ |
| Mar 6, 2026 | William John Sibold | President and CEO | Sale | 1.7K | $431.94 | $718.3K | SEC ↗ |
| Mar 6, 2026 | Shannon T Kelley | General Counsel | Sale | 360 | $431.94 | $155.5K | SEC ↗ |
| Mar 6, 2026 | Carole Huntsman | Chief Commercial Officer | Sale | 419 | $431.94 | $181.0K | SEC ↗ |
| Mar 6, 2026 | Taub Rebecca | Director | Sale | 491 | $431.94 | $212.1K | SEC ↗ |
| Mar 2, 2026 | Mardi Dier | EVP and CFO | Sale | 1.2K | $427.21 | $505.4K | SEC ↗ |
| Jan 26, 2026 | Carole Huntsman | Chief Commercial Officer | Sale | 910 | $493.78 | $449.3K | SEC ↗ |
| Jan 26, 2026 | William John Sibold | President and CEO | Sale | 1.6K | $492.42 | $776.5K | SEC ↗ |
| Jan 26, 2026 | Taub Rebecca | Director | Sale | 647 | $492.42 | $318.6K | SEC ↗ |
| Jan 20, 2026 | Shannon T Kelley | General Counsel | Sale | 692 | $497.36 | $344.2K | SEC ↗ |
| Jan 20, 2026 | Taub Rebecca | Director | Sale | 2.2K | $490.77 | $1.1M | SEC ↗ |
| Jan 13, 2026 | Paul A Friedman | Director | Sale | 280 | $551.24 | $154.3K | SEC ↗ |
| Jan 13, 2026 | Paul A Friedman | Director | Sale | 24.5K | $522.39 | $12.8M | SEC ↗ |
| Jan 13, 2026 | Taub Rebecca | Director | Sale | 240 | $550.33 | $132.1K | SEC ↗ |
| Jan 13, 2026 | Taub Rebecca | Director | Sale | 18.4K | $522.40 | $9.6M | SEC ↗ |
| Dec 12, 2025 | Paul A Friedman | Director | Sale | 24.8K | $552.18 | $13.7M | SEC ↗ |
| Dec 12, 2025 | Taub Rebecca | Director | Sale | 18.6K | $552.15 | $10.3M | SEC ↗ |
| Dec 4, 2025 | William John Sibold | President and CEO | Sale | 2.4K | $575.34 | $1.4M | SEC ↗ |
| Dec 3, 2025 | Mardi Dier | EVP and CFO | Sale | 4.2K | $578.34 | $2.4M | SEC ↗ |
Showing the 25 most recent of 104 Form 4 filings for MADRIGAL PHARMACEUTICALS, INC..
Most active MDGL insiders
- Taub Rebecca14 filings
- Paul A Friedman12 filings
- Robert E. Waltermire10 filings
- Fred B Craves9 filings
- William John Sibold9 filings
Ask anything about MDGL insider activity
Use Trabud's AI agent to query MADRIGAL PHARMACEUTICALS, INC.'s Form 4 history in plain English — "Show me MDGL CEO purchases this year" or compare it against any other ticker.
Open the AI agentMDGL insider trading FAQ
Are MADRIGAL PHARMACEUTICALS, INC. insiders buying or selling?
In the last 12 months, MADRIGAL PHARMACEUTICALS, INC. insiders reported 0 open-market purchases ($0) and 28 sales ($81.5M) — net selling of $81.5M. Since June 2018, Trabud has recorded 104 Form 4 filings for MDGL: 12 buys ($162.0M) and 92 sells ($769.5M). Over the full record that is net selling of $607.4M.
How many insiders trade MDGL stock?
18 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for MADRIGAL PHARMACEUTICALS, INC.. The most recent filing was accepted on Sep 11, 2026.
Where does Trabud get MDGL insider trading data?
All MDGL insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.